Switzerland: HPAPI and ADC Solutions Lonza Inaugurates New Plant for ADC Payload Manufacturing
Launched virtually, the new facility located at the Visp site in Switzerland will be responsible for manufacturing antibody-drug conjugate drug-linkers. The plant will also strengthen the overall bioconjugation capabilities of the firm in the region.
Basel/Switzerland – Lonza has recently inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload) manufacturing at the Visp (CH) site. This first manufacturing suite handles compounds with occupational exposure levels down to 1ng/m3 and is dedicated to the manufacturing platform for ADC drug linkers. This expansion underlines the strategic position of ADCs in the Lonza portfolio, with the company developing and producing all components of these increasingly important cancer treatments: cytotoxic payloads, antibodies and the required linkers on one site.
Due to Covid-19 measures, the opening was held as a virtual opening ceremony, connecting multiple customers and Lonza sites worldwide after the first process validation was completed successfully and manufacturing for in-market supply started.
The first of two state-of-the-art, highly-potent API (HPAPI) suites supports a global biopharmaceutical partner by securing their long-term supply of highly-potent ADC payloads. The suite has been in operation since March of this year. A second suite will become available to other customers early in 2021 for similar HPAPI and payload development and manufacturing programmes.
These new suites will extend the options for companies developing APIs with even higher potencies. Moreover, they will increase Lonza’s capabilities to provide fully scalable HPAPI and ADC solutions from lab to commercialisation, supporting the accelerated timelines that many drug programmes in this category require.
Maurits Janssen, Strategic Business Development Small Molecules, Lonza: “Supply from the facility is critical, and by supporting one of our global partners in the oncology field, we are enabling the treatment of many cancer patients. Oncology continues to be the leading indication in biopharma and a key driver for highly potent ingredients such as antibody-drug conjugates. We continue to add capabilities and capacity to meet the development and manufacturing needs of our partners in this field to answer to their increasing demand.”
Gordon Bates, President Small Molecules, Lonza: “This partnership is a great example of how we can support both early and commercial-stage biopharmaceutical companies through innovation in manufacturing technology and flexible business models. Our customers developing highly potent and increasingly complex medicines need a partner whom they can trust to handle these toxic substances throughout their lifecycle and to deliver in sync with their needs, whether for clinical or for commercial supply. Our partner has recognised the value in combining expertise in biologics and chemistry on one site and this investment has expanded our collaboration.”